The study is being conducted in healthy male and female volunteers at a single site in the US under an investigational new drug (IND) application recently allowed by the the US Food and Drug Administration.
The aim of the Phase 1 study will be to utilize the PK-PD relationship of RPC1063 to accurately select dose levels for Phase 2 evaluation.
Receptos president and CEO Faheem Hasnain said the progression of RPC1063 into Phase 1 development marks the evolution of Receptos into a clinical stage organization.
"The exceptional performance of the development team at Receptos has been demonstrated by their ability to initiate clinical trials for our lead compound within 14 months of our Series A funding round," said Faheem Hasnain, President and Chief Executive Officer of Receptos," Hasnain said.